Allenex jan-dec: 112,7 msek (98,7) net sales

For the fourth quarter October - December

  · Net sales for the quarter amounted to SEK 27.4 million (27.5). Sales were
impacted by a negative currency effect of SEK 1.2 million compared to the same
period last year. Adjusted for currency effects, the growth rate was 4 percent.
  · Operating income (EBIT) for the quarter was SEK 0.6 million (-76.0), with
currency effects having a negative impact of SEK 1.4 million on results compared
to the same period last year. (In 2011, earnings were impacted by impairment
losses of SEK 74.6 million.)
  · Operating margin for the quarter was 2 percent.
  · Earnings after tax for the quarter was SEK 0.9 million (-71.7).
  · Earnings per share for the quarter, basic and diluted, were SEK 0.03 (
-0.75).

        For the January - December period

  · Net sales for the year amounted to SEK 112.7 million (98.7), corresponding
to an increase of 14 percent compared to last year. (Olerup GmbH became a part
of the group on June 1, 2011). Sales compared to 2011 were impacted by a
negative currency effect of SEK 2.3 million.
  · Operating income (EBIT) for the year was SEK 7.9 million (-88.1), with
currency effects having a negative impact of SEK 3.7 million on results compared
to last year. (2011 results were charged with impairment losses of SEK 74.6
million.)
  · Operating margin for the year was 7 percent.
  · Earnings after tax for the year was SEK 0.3 million (-504.7). (2011 results
were charged with impairment losses of SEK 489.3 million).
  · Earnings per share for the year, basic and diluted, were SEK 0.04 (-7.23).

        Significant events after the year end

  · The Allenex subsidiary AbSorber received an EU grant of EUR 215,000 over a
three-year period
  · Allenex received a breakthrough order in the U.S. for SBT Resolver™ from a
leading HLA typing laboratory. The yearly sales value is estimated at more than
SEK 2 million.


CEO Anders Karlsson’s comments on the fourth quarter 2012:
“In 2012, Allenex reset its course to focus on transplantation diagnostics. The
organization is now streamlined to underpin the company’s new strategy and
adapted to meet the needs of our customers. Sales increased during the year and
we achieved a number of key business milestones. We see continued growth in
important markets for the company’s largest product Olerup SSP. The roll out of
the SBT Resolver™ product line from our Australian partner Conexio Genomics has
been intensive and during the year several centers have adopted the product.
After the year end, we received a breakthrough order in the U.S., from a major
leading transplantation center, with several other key American centers shortly
expected to follow suit. We see this as a key launch milestone, with the
possibility of gaining other major centers in other parts of the world as
customers. Unfortunately, the strong Swedish kronor has had a negative impact on
sales, primarily during the second half of 2012.”

For more information please contact:
Anders Karlsson, CEO Allenex AB, ph: +4670-918 00 10, e-mail:
anders.karlsson@allenex.se
Yvonne Axelsson, CFO Allenex AB ph: +468-508 939 72, e-mail
yvonne.axelsson@allenex.se

Allenex AB discloses the information provided herein pursuant to the Securities
Markets Act and /or the Financial Instruments Trading Act. The information was
submitted for publication on Feb 21, 2013, at 14.00 CET. Allenex is a life
science-company that develops, manufacture, market and sell products for safer
transplants of organs and bone marrow on the global market. Allenex is listed on
NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the
Allenex group.